Preclinical and clinical studies indicate that the immune microenvironment of HER2 + tumors is driven by tumor infiltrating lymphocytes and macrophages, which can produce pro-inflammatory cytokines [2–4]. This evidence concerns the gene ERBB2 and neoplasm.